Nanotechnology in Health Care : Market Research Report

Nanotechnology in Health Care

Published: Feb. 1, 2007

INTRODUCTION
I. EXECUTIVE SUMMARY
II. MARKET ENVIRONMENT: General; Macroeconomic Outlook; Demographic Trends; Health Care Trends; Medical Conditions; Chronic Conditions; Acute Conditions; Health Insurance & Reimbursement; National Health Expenditures; Medical Providers; Hospitals; Outpatient Facilities; Physicians; Dentists; Other Health Care Providers; Patient Activity; Surgical Procedures; Outpatient Visits; Diagnostic Tests; Medical Product Demand; Pharmaceuticals; Diagnostic Products; In Vitro Diagnostic (IVD) Products; In Vivo Imaging Agents; Medical Supplies & Devices
III. NANOTECHNOLOGY OVERVIEW: General; Product Groups; Regulatory Trends; Pharmaceuticals; Diagnostic Products; Medical Supplies & Devices; Current Good Manufacturing Practices (cGMPs); Investment Environment; International Markets
IV. NANOMATERIALS: General; Monoclonal Antibodies; DNA Materials; Nanoparticles; Nanotubes & Nanowires; Dendrimers; Fullerenes; Quantum Dots; Other Nanomaterials
V. NANOMEDICINES: General; Product Groups; Monoclonal Antibodies; Marketed Products; Products in Development; Polymer-Based Nanomedicines; Marketed Products; Developmental Activities; Other Nanomedicines; Nanocrystal Therapies; Liposomes; Marketed Products; Products in Development; All Other Nanomedicines; Marketed Products; Products in Development
VI. NANODIAGNOSTICS: General; In Vitro Diagnostics; Monoclonal Antibodies; Immunological Reagents & Test Kits; Immunohematology; Cellular Analysis; Research Reagents; DNA Testing Materials; Amplified DNA Probes; Direct DNA Probes; DNA Microarrays; Other DNA Testing Materials; In Vivo Diagnostics; MRI Imaging Agents; Advanced Magnetics; Kereos; Other Development Stage Compounds; Other Diagnostic Imaging Agents
VII. NANOTECH MEDICAL SUPPLIES & DEVICES: General; Orthopedic Products; Bone Cement; Bone Substitutes; Orthopedic Implants; Wound Management Products; Wound Closures; Wound Dressings; Dental Products; Surgical Products; Ophthalmic Products; Other Nanotechnology Medical Supplies & Devices; Disinfectants; Cardiac Implants; Cochlear Implants; Catheters; Neuron Regenerators; Artificial Skin
VIII. APPLICATIONS: General; Cancer; Epidemiological Trends; Nanomedicines; Diagnostics; Central Nervous System Conditions; Epidemiological Trends; Nanomedicines; Diagnostics; Medical Supplies & Devices; Infective & Parasitic Conditions; Epidemiological Trends; Nanomedicines; Diagnostics; Cardiovascular Conditions; Epidemiological Trends; Nanomedicines; Diagnostics; Medical Supplies & Devices; Other Applications
IX. INDUSTRY STRUCTURE: General; Market Share; Competitive Strategies; Licensing Agreements; Research & Development; Marketing & Distribution; Manufacturing; Company Profiles; Abbott Laboratories; Abraxis BioScience Incorporated; Access Pharmaceuticals Incorporated; Advanced Magnetics Incorporated; Advion BioSciences Limited; Alnis BioSciences Incorporated; Altair Nanotechnologies Incorporated; ALZA Corporation, see Johnson & Johnson; American BioScience, see Abraxis BioScience; American Pharmaceutical Partners, see Abraxis BioScience; Amgen Incorporated; Angstrom Medica Incorporated; Arrowhead Research Corporation; AstraZeneca plc; Avidimer Therapeutics Incorporated; Baxter International Incorporated; Bayer AG; BioDelivery Sciences International; BioForce Nanosciences Holdings Incorporated; Biogen Idec Incorporated; Biophan Technologies Incorporated; BioSante Pharmaceuticals Incorporated; BioTrove Incorporated; Bristol-Myers Squibb Company; C Sixty, see Carbon Nanotechnologies; Carbon Nanotechnologies Incorporated; CritiTech Incorporated; Crystalplex Corporation; CytImmune Sciences Incorporated; Danaher Corporation; Dendritic NanoTechnologies, see Starpharma Holdings; Dow Chemical Company; Elan Corporation plc; Enzon Pharmaceuticals Incorporated; eSpin Technologies Incorporated; Ferro Corporation; Flamel Technologies SA; GeneFluidics Incorporated; Genentech Incorporated; Health Plus International Incorporated; Improvita Health Products Incorporated; Insert Therapeutics, see Arrowhead Research; International Business Machines Corporation; Intradigm Corporation; Introgen Therapeutics Incorporated; Invitrogen Corporation; Johnson & Johnson; Kerr Corporation, see Danaher Corporation; Lavipharm Corporation; Luna Innovations Incorporated; Mallinckrodt, see Tyco International; Merck & Company Incorporated; Mersana Therapeutics Incorporated; NanoBio Corporation; NanoBioMagnetics Incorporated; NanoBioTec GmbH; Nanobiotix SA; NanoCarrier Company Limited; NanoCure Corporation, see Avidimer Therapeutics; NanoDel Technologies GmbH; Nanodisc Incorporated; Nanogen Incorporated; NanoHorizons Incorporated; NanoInk Incorporated; NanoLab; NanoMaterials Technology Pte Limited; NanoMed Pharmaceuticals Incorporated; Nanomix Incorporated; Nanopharma Corporation, see Mersana Therapeutics; Nanoplex Technologies, see Oxonica Limited; Nanospectra Biosciences Incorporated; Nanosys Incorporated; Nektar Therapeutics; Novagali Pharma SA; Novavax Incorporated; NUCRYST Pharmaceuticals Corporation; Ortho Biotech Products, see Johnson & Johnson; Orthovita Incorporated; Oxonica Limited; Pfizer Incorporated; PharmaSol GmbH; pSivida Limited; Quantum Dot, see Invitrogen Corporation; Roche Holding Limited; Salvona LLC; Sensatex Incorporated; Siemens AG; SkyePharma plc; Smiths Group plc; Soliqs, see Abbott Laboratories; Spire Corporation; Starpharma Holdings Limited; Sybron Dental Specialties, see Danaher; Tailored Materials Corporation Incorporated; Teva Pharmaceutical Industries Limited; 3M Company; Triton BioSystems Incorporated; Tyco International Limited; Wyeth
LIST OF TABLES
SECTION I -- EXECUTIVE SUMMARY: Summary Table
SECTION II -- MARKET ENVIRONMENT: 1 Macroeconomic Indicators; 2 Population by Age Group; 3 Medical Conditions by Duration & Type; 4 National Health Expenditures by Type; 5 Selected Medical Providers by Type; 6 Selected Patient Activity by Type; 7 Medical Product Demand by Type; 8 Pharmaceutical Demand by Therapeutic Class; 9 Diagnostic Product Demand by Type
SECTION III -- NANOTECHNOLOGY OVERVIEW: 1 Nanotechnology Medical Product Demand by Type; 2 R&D Investment in Nanotechnology Medical Products
SECTION V -- NANOMEDICINES: 1 Nanomedicine Demand by Therapeutic Class; 2 Nanomedicine Demand by Product Group; 3 Therapeutic Monoclonal Antibody Demand; 4 Therapeutic Monoclonal Antibodies Approved for US Sale; 5 Therapeutic Monoclonal Antibodies -- US Sales by Product, 2001 & 2006; 6 Polymer-Based Nanomedicine Demand; 7 Polymer-Based Nanomedicines Approved for US Sale; 8 Polymer-Based Nanomedicines -- US Sales by Product, 2001 & 2006; 9 Other Nanomedicine Demand; 10 Nanocrystal Medicines Approved for US Sale; 11 Liposomal Therapies Approved for US Sale; 12 Other Nanomedicines Approved for US Sale
SECTION VI -- NANODIAGNOSTICS: 1 Nanotechnology-Based Diagnostic Product Demand by Segment; 2 Nanotechnology In Vitro Diagnostic Product Demand by Type; 3 Monoclonal Antibody-Based Diagnostic Product Demand by Type; 4 Monoclonal Antibody-Based Immunological Reagent & Test Kit Demand; 5 Monoclonal Antibody-Based Immunohematology Reagent & Test Kit Demand; 6 Monoclonal Antibody-Based Cellular Analysis Reagent & Test Kit Demand; 7 Monoclonal Antibody-Based Research Reagent Demand; 8 DNA Testing Material Demand by Type; 9 Amplified DNA Probe Demand; 10 Direct DNA Probe Demand; 11 DNA Microarray Demand; 12 Other DNA Testing Material Demand by Type; 13 Nanotechnology In Vivo Diagnostic Product Demand
SECTION VII -- NANOTECH MEDICAL SUPPLIES & DEVICES: 1 Nanotechnology Medical Supply & Device Demand by Product Group; 2 Nanotechnology Orthopedic Product Demand; 3 Nanopolymer Bone Cement Demand; 4 Nanomaterial Bone Substitute Demand; 5 Nanotechnology Orthopedic Implant Demand by Type; 6 Nanotechnology Wound Management Product Demand; 7 Nanotechnology Wound Closure Demand; 8 Nanotechnology Wound Dressing Demand; 9 Nanotechnology Dental Product Demand; 10 Nanotechnology Surgical Product Demand; 11 Nanotechnology Ophthalmic Product Demand; 12 Other Nanotechnology Medical Supply & Device Demand
SECTION VIII -- APPLICATIONS: 1 Nanotechnology Medical Product Demand by Application; 2 Nanotechnology Cancer Product Demand; 3 Nanotechnology Central Nervous System Product Demand; 4 Nanotechnology Product Demand for Infective & Parasitic Conditions; 5 Nanotechnology Cardiovascular Product Demand; 6 Nanotechnology Medical Product Demand in Other Applications by Product Class & Type
SECTION IX -- INDUSTRY STRUCTURE: 1 Selected Cooperative Agreements
LIST OF CHARTS
SECTION III -- NANOTECHNOLOGY OVERVIEW: 1 Nanotechnology Medical Product Demand by Type, 2011
SECTION V -- NANOMEDICINES: 1 Nanomedicine Demand by Therapeutic Class, 2011; 2 Nanomedicine Demand by Product Group, 2011
SECTION VI -- NANODIAGNOSTICS: 1 Nanodiagnostics Demand by Product Group, 2011
SECTION VII -- NANOTECH MEDICAL SUPPLIES & DEVICES: 1 Nanotech Medical Supply & Device Demand by Product Group, 2011
SECTION VIII -- APPLICATIONS: 1 Nanotechnology Medical Product Demand by Application, 2011
SECTION IX -- INDUSTRY STRUCTURE: 1 Nanotechnology Medical Product Market Share, 2006

Abstract

US demand to rise over 17% annually through 2011
US demand for nanotechnology health care products will grow over 17 percent per year to $50 billion in 2011. Afterwards, the increasing flow of new nanomedicines, nanodiagnostics, and nanotech-based medical supplies and devices into the US marketplace will boost demand to $107 billion in 2016 and $225 billion in 2021. The critical need for new or improved therapies for many medical conditions will promote the adaptation of nanotechnology to an expanding number of pharmaceuticals. The total market for nanomedicines will command strong growth over the long term, rising to $41 billion in 2011, $84 billion in 2016 and $175 billion in 2021. Treatments based on humanized monoclonal antibodies, nanopolymers and nanoproteins will drive gains, with compounds for cancer, neurological disorders, viral infections and ischemic heart diseases leading new product introductions and growth opportunities. Eventually, pharmaceutical applications of nanotechnology will extend into all major therapeutic classes, encompassing numerous formulations and delivery systems.

Nanodiagnostics to grow 13% per year through 2011
Advances in nanotechnology will also contribute significant improvements to the quality and performance of medical diagnostic products. Nanosized labels, probes and biosensors will greatly enhance the speed, accuracy, capabilities and cost-effectiveness of in vitro diagnostic testing, drug discovery and medical research procedures. Nanoparticle formulations of superparamagnetic iron oxide, gadolinium, perfluorocarbon and specialty polymers will broaden in vivo imaging capabilities by enabling the detection of tumors, plaque, genetic defects and other disease states at much earlier stages and with lower, safer concentrations of injected compounds. Reflecting these advantages and new offerings, demand for nanodiagnostic products is projected to increase over 13 percent per year to 2011 and continue rising at a double digit annual pace through 2021.

Please Note: Freedonia requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Nanotechnology in Health Care

Table of Contents

Abstract